Karyopharm Therapeutics
KPTI
49 hedge funds and large institutions have $13.7M invested in Karyopharm Therapeutics in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 30 reducing their positions, and 42 closing their positions.
512% more call options, than puts
Call options by funds: $581K | Put options by funds: $95K
5.23% less ownership
Funds ownership: 48.27% → 43.04% (-5.2%)
44% less funds holding
Funds holding: 87 → 49 (-38)
67% less capital invested
Capital invested by funds: $41.2M → $13.7M (-$27.5M)
73% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 30
90% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.3M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$1.19M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.04M |
| 4 |
EP
Eversept Partners
New York
|
+$1.01M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$716K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.91M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.08M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$863K |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$808K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$643K |
KPTI Hedge Fund Activity: Q1 2025 in Review
49 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2025, worth a combined $13.7M — down 67% from $41.2M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of KPTI and 4 opened new positions — a net loss of 38 holders — while 30 trimmed existing stakes and 8 added.
The largest buyer was JP Morgan Chase, adding an estimated $1.3M. The largest seller was Morgan Stanley, cutting an estimated $1.91M.
- 49 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2025, down from 87 in Q4 2024.
- Funds reported $13.7M of Karyopharm Therapeutics stock for Q1 2025, down 67% quarter-over-quarter.
- 4 funds opened new Karyopharm Therapeutics positions in Q1 2025 and 42 closed out, a net change of -38 holders.
- The largest Karyopharm Therapeutics buyer in Q1 2025 was JP Morgan Chase, an estimated $1.3M added.
- The largest Karyopharm Therapeutics seller in Q1 2025 was Morgan Stanley, an estimated $1.91M sold.
Based on aggregated 13F filings for Q1 2025.